- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Purpose Bitcoin ETF
Silver47 Exploration
Syntheia
CI Galaxy Bitcoin ETF
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Novartis and Amgen lead the migraine market after a second late-stage trial yielded positive results.
For many migraine sufferers, the best remedy has been to turn out the lights and go to bed. But dark and rest don’t make money for drug companies—and given the paucity of effective migraine medications on the market, many in the space are racing to provide another option to patients.
Teva (NYSE:TEVA), Eli Lilly (NYSE:LLY), Alder Biopharmaceuticals (NASDAQ:ALDR) and Allergan (NYSE:AGN) are all hard at work on new migraine medications—but it is Novartis (NYSE:NVS) and Amgen (NASDAQ:AMGN) that have surged into the lead after a second late-stage trial yielded positive results.
Episodic migraine sufferers reported fewer headaches per month while on the pair’s investigational drug, erenumab (or AMG 334). On enrollment, these patients were experiencing approximately eight migraine days per month. The drug appears to have nearly halved that number: patients on the 70 milligram dose experienced 3.2 fewer migraine days a month and those on the 140 milligram dose reported a slighter higher benefit—3.7 fewer migraine days per month.
That’s impressive in an of itself, but particularly when you consider what is determined “clinically significant” in this market. As FierceBiotech has reported, clinicians believe that even a one day reduction in migraines per week is a major development, considering how debilitating these severe headaches can be.
The results build on earlier promising trial data, which also examined erenumab’s efficacy in treating chronic migraines. Taken all together, that data has experts predicting great success for the companies’ new product: Jefferies analyst Jeffrey Holford has predicted drug sales as high as $1.5 billion, Reuters reported.
How will those profits be split between Novartis and Amgen? According to the collaboration agreement, Amgen owns the American, Canadian and Japanese markets, with Novartis holding sales rights in the rest of the world.
Investors can expect to see drug shipped as soon as next year.
Don’t forget to follow us @INN_LifeScience for real-time news updates.
Securities Disclosure: I, Chelsea Pratt, hold no direct investment interest in any company mentioned in this article.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.